Ketamine and Esketamine for Postpartum Depression: Promising Data, Real Gaps, and What It Means for Your Practice
Synopsis: Postpartum depression affects an estimated 10 to 20 percent of mothers and remains significantly undertreated. This clinician-focused evidence review covers what the latest randomized controlled trials and meta-analyses show about racemic ketamine and esketamine in the peripartum setting, including the critical prevention versus treatment distinction that shapes how this literature should be read, the ethical considerations every provider needs to understand, and five research gaps that define the limits of what we currently know.
Key Takeaways:
Racemic ketamine shows a short-term preventive signal for postpartum depression in high-risk obstetric populations but the benefit attenuates at four to six weeks and is inconsistent across trials.
Esketamine shows a more consistent and durable preventive effect, particularly in women with existing antenatal depressive symptoms, with a landmark 2024 BMJ trial reporting a number needed to treat of approximately five.
Critically, almost all of this data is about prevention around the time of cesarean delivery, not treatment of established postpartum depression in the outpatient setting. The woman sitting in your clinic with postpartum depression is largely absent from this research.
Cautious optimism is warranted. Broad clinical adoption is not.
Professional Education Disclaimer: This content is intended exclusively for licensed healthcare professionals and should not be used by patients for self-treatment or self-education. The information presented reflects current regulatory developments and should not replace clinical judgment, professional training, or comprehensive research. Healthcare providers must conduct their own due diligence, consult current literature, and evaluate treatment approaches within their specific practice context and regulatory environment. This educational content does not constitute medical or legal advice for specific patients or clinical situations.
Note: The research discussed in this post involves specific clinical populations, primarily women undergoing cesarean delivery in controlled hospital settings. These findings should not be extrapolated to routine outpatient clinical practice without careful consideration of your patient population, your clinical setting, and the current standard of care. If you are a patient or family member seeking guidance on postpartum depression treatment, please speak with a qualified healthcare provider.
🎙️ THIS POST IS BASED ON
Ketamine Startup Podcast: Episode 064
What the Research Says About Ketamine for Postpartum Depression. An evidence-based review of what the current literature tells us about ketamine and esketamine specifically for postpartum depression, what it does not yet tell us, and what it means for how you think about this population in your practice.
Listen to the Episode →
Postpartum depression affects an estimated 10 to 20 percent of mothers and remains significantly undertreated. As public cases bring maternal mental health into national conversation, clinicians are asking harder questions about what ketamine and esketamine research actually shows and what it means for practice.
Introduction
Postpartum depression affects somewhere between 10 and 20 percent of mothers, and that number is likely an undercount. It goes unscreened. It goes underreported. It causes impaired bonding with infants, developmental consequences for children, profound functional impairment, and in the most severe cases, suicide.
The name Lindsay Clancy entered public consciousness in a case that brought maternal mental health into a painful and very public national conversation. We are not here to speculate about that case. But cases like that, when they reach the public in the way that one did, tend to prompt important clinical questions within our professional community. Questions we think are worth answering seriously.
Questions like: what role, if any, do ketamine and esketamine have in postpartum depression? What does the research actually say? Is this a population our practices should be thinking about more carefully?
Those are the questions we are answering in this post. And the honest answer, as you will see, is more nuanced than most of what is currently circulating on this topic.
Table of Contents
Postpartum depression, postpartum psychosis, and perinatal depression are distinct clinical entities that require different treatment considerations. Understanding the terminology and the cesarean delivery research context is essential before reading the ketamine and esketamine evidence in this space.
Getting the Clinical Foundation Right
Before we get into the evidence, let us make sure we are working from the same clinical foundation, because the terminology here matters and it is easy to conflate terms that describe genuinely different things.
Postpartum depression, or PPD, is a major depressive episode temporally associated with childbirth. DSM-5 uses the specifier "with peripartum onset" if symptoms begin during pregnancy or within four weeks of delivery, but in clinical practice PPD is typically understood as any depression emerging within the first year after birth. It presents with persistent low mood, loss of interest, fatigue, difficulty bonding with the baby, and in severe cases suicidal ideation.
This is distinct from postpartum psychosis, a rare but serious psychiatric emergency involving hallucinations, delusions, and disorganized thinking, which is generally considered a contraindication or at minimum a situation requiring extreme caution for ketamine therapy.
The broader and more clinically accurate frame is perinatal depression, which encompasses depressive episodes during pregnancy (antenatal depression) as well as the postpartum period. This distinction matters for how we read the research, because a significant portion of the trials we are about to discuss focus specifically on women who already have antenatal depressive symptoms going into delivery, not just women who develop depression after the fact.
One population that appears consistently throughout this literature is women delivering by cesarean section. Cesarean delivery is associated with higher rates of postpartum pain, which is itself a risk factor for depression and engages overlapping neurobiological pathways with mood regulation. It also creates a unique clinical window: the operating room. When a woman is already receiving anesthesia for a cesarean, there is a practical opportunity to administer an adjunct medication like ketamine or esketamine as part of that anesthetic protocol. That is exactly how most of the trials in this space were designed.
And that brings us to why ketamine and esketamine are conceptually interesting here in the first place. Traditional antidepressants take weeks to reach therapeutic effect. For a mother in the immediate postpartum period, weeks is a long time, both for her and for her infant. Ketamine and esketamine act as NMDA receptor antagonists and can produce antidepressant effects within hours, sometimes after a single infusion. Add to that ketamine's analgesic properties that are directly relevant in a post-surgical population, and you can see why researchers started asking whether it could do two things at once: manage pain and protect against depression simultaneously.
That is the conceptual appeal. Whether the data supports it is where things get more complicated.
The Most Important Distinction in This Conversation
Before we walk through the evidence, we need to name something clearly, because it shapes how everything else should be read.
Almost all of the peripartum ketamine research is studying prevention, not treatment.
These are trials where ketamine or esketamine is administered around the time of cesarean delivery as an anesthetic or analgesic adjunct, with the goal of reducing the risk of postpartum depression developing in the days and weeks that follow. That is fundamentally different from what most providers in our community are doing in their practices, where they are treating patients who already have an established diagnosis of depression.
The mixed peripartum data we are about to discuss does not address ketamine's efficacy for treatment-resistant depression, which rests on a separate and well-established body of evidence in major depressive disorder and TRD outside the perinatal period. Those are different clinical questions with different evidence bases, and conflating them creates confusion that does not serve patients or providers.
With that framing in place, let us look at what the trials actually show.
Racemic Ketamine: Mixed and Inconsistent Signals
The story starts with a straightforward question: if you give a woman a dose of ketamine during her cesarean section, does it reduce her risk of developing postpartum depression? The honest answer is: sometimes, and the data are genuinely mixed.
On the negative side, Xu et al. published a randomized, double-blind, placebo-controlled trial in 2017 in the Archives of Gynecology and Obstetrics. Three hundred and thirty women undergoing cesarean under neuraxial anesthesia received either a single low-dose bolus of IV ketamine or saline placebo intraoperatively. The result: no significant difference in PPD incidence or depression scores between the groups at either three days or six weeks postpartum. Slight improvement in pain scores in the ketamine group, but no detectable antidepressant or prophylactic effect on mood.
Then in 2019, a larger trial published in Psychiatry Research told a different story. Six hundred and fifty-four women undergoing cesarean received a higher dose of IV ketamine given ten minutes after childbirth. Here the results were positive: lower rates of postpartum blues and PPD in the ketamine group compared to controls at six weeks. The effect was strongest in women who had experienced significant stress during pregnancy, those with antenatal depressive symptoms going into delivery, and those who had reported suicidal ideation. The women already at highest risk seemed to benefit most.
A 2020 trial in Brain and Behavior added a modestly positive signal, showing reductions in depressive symptom scores at short-term follow-up with a sub-anesthetic intraoperative ketamine infusion during cesarean. The effect size was modest and durability limited.
In 2022, Monks et al. published a small pilot feasibility study in BMC Pregnancy and Childbirth comparing IV versus subcutaneous ketamine against placebo in 23 women. It was explicitly designed to test feasibility and tolerability rather than efficacy and was not powered to detect differences in PPD rates. It found no statistically significant difference between groups, but demonstrated that both routes of administration were acceptable and well tolerated, information that matters for how future larger trials are designed.
When you step back and look at the meta-analytic picture, it becomes clearer, even if not clean.
A 2025 updated systematic review and meta-analysis by Darwish et al. in BMC Pregnancy and Childbirth pooled 21 studies and found a statistically significant reduction in short-term PPD risk at approximately one week postpartum for racemic ketamine. But at longer follow-up at four to six weeks, that benefit disappeared. Only esketamine maintained a statistically significant reduction in PPD incidence at those longer time points.
The bottom line on racemic ketamine in the peripartum setting: there is a signal, particularly in high-risk women and at higher doses, but it is inconsistent across trials, it attenuates over time, and the meta-analytic evidence does not support routine prophylactic use at this point.
Intravenous esketamine administered perioperatively around the time of cesarean delivery has shown more consistent and durable reductions in postpartum depression risk than racemic ketamine, with a landmark 2024 BMJ trial reporting a number needed to treat of approximately five in high-risk obstetric populations.
Esketamine: A More Consistent Preventive Story
A quick pharmacology note before we get into the trials. Racemic ketamine is a mixture of two mirror-image molecules: the S-enantiomer and the R-enantiomer. Esketamine, also known as S-ketamine, is the S-enantiomer in isolation. It has stronger binding affinity at the NMDA receptor than the R-enantiomer, which means it may produce more potent NMDA antagonism at equivalent or lower doses. That is the pharmacological rationale for why researchers started asking whether esketamine might outperform racemic ketamine in this setting.
We also want to be clear about something upfront that comes up in our community. The esketamine data we are discussing here is not about Spravato, the branded intranasal esketamine product. The trials we are covering used intravenous esketamine formulations integrated into anesthetic and analgesic protocols. They were funded by government and hospital sources, not pharmaceutical companies, which means they stand largely on their own without commercial conflict-of-interest concerns.
The first meaningful signal came from a 2022 randomized controlled trial in BMC Anesthesiology that added low-dose S-ketamine to patient-controlled intravenous analgesia, what anesthesiologists call PCIA, after cesarean section. Roughly 275 women were analyzed. The result: lower PPD incidence at 3 and 14 days postpartum and improved analgesia in the S-ketamine group, without a significant increase in adverse events. A modest intervention with a meaningful preventive signal.
In 2023, a dose-finding study in the Journal of Affective Disorders enrolled approximately 240 women with prenatal depression undergoing cesarean, randomized to low-dose esketamine, high-dose esketamine, or placebo. Results showed a dose-response relationship: both esketamine regimens reduced PPD incidence at seven days, but only the higher dose maintained that benefit out to 42 days postpartum. This began to answer the durability question that racemic ketamine trials had struggled with.
Then in 2024, Wang et al. published what may be the landmark trial in this space, in the BMJ. A rigorous double-blind placebo-controlled RCT across five tertiary hospitals in China. Three hundred and sixty-four mothers, all with Edinburgh Postnatal Depression Scale scores indicating existing prenatal depressive symptoms, were randomized to receive either IV esketamine administered over 40 minutes after cord clamping or placebo. The primary outcome was the rate of major depressive episodes at 42 days postpartum, confirmed by structured clinical interview. Major depressive episodes occurred in 6.7 percent of the esketamine group compared to 25.4 percent in the placebo group. The number needed to treat to prevent one major depressive episode at 42 days was approximately five, clinically meaningful in this high-risk obstetric population. Neuropsychiatric adverse events including dissociation and dizziness occurred more frequently in the esketamine group but resolved within 24 hours without treatment.
Also in 2024, a JAMA Network Open trial on perioperative adjunctive esketamine during elective cesarean delivery in 298 women showed reduced depressive symptoms and lower early PPD screening positivity in the esketamine group, though the effect attenuated over time.
In 2025, Ren et al. published another JAMA Network Open trial looking at intraoperative esketamine infusion during cesarean in 308 women. PPD incidence at six weeks was 10.4 percent in the esketamine group versus 19.5 percent in the control group, reaching statistical significance. Notably the benefit was not evident at one week but emerged clearly by six weeks, a different temporal pattern than earlier trials that adds nuance to our understanding of timing and duration of effect.
When the meta-analytic data is pooled, the picture for esketamine is considerably more consistent than racemic ketamine. The 2025 Darwish meta-analysis found esketamine was the only agent that maintained a statistically significant reduction in PPD incidence at the four to six week follow-up window. A separate 2025 esketamine-focused meta-analysis by Shi et al. in the Journal of Affective Disorders covering 13 studies and over 2,700 patients reinforced this pattern: lower PPD risk and lower EPDS scores at both one and six weeks, with a side-effect profile of transient dizziness, blurred vision, and hallucinations consistently described as short-term and self-resolving.
Before we move on, one critical limitation applies to almost everything we have just discussed.
The overwhelming majority of this research was conducted in China, in tertiary hospital settings, with women undergoing planned or emergency cesarean delivery who were screened for prenatal depressive symptoms before enrollment. That is a very specific clinical context. It does not tell us how these findings translate to a broader and more diverse U.S. patient population, to vaginal deliveries, to women without prior depressive symptoms, or to office-based outpatient ketamine practice. That gap matters significantly, and we will come back to it.
| Racemic ketamine vs esketamine: peripartum evidence comparison | ||||
| Agent | Key trials | Short-term benefit | Longer-term benefit | Bottom line |
|---|---|---|---|---|
| Racemic ketamine | Xu et al. 2017 (negative); Psychiatry Research 2019 (positive, high-risk women); Brain and Behavior 2020 (modest); Monks et al. 2022 (feasibility only); Darwish et al. 2025 meta-analysis | Short-term signal at approximately one week postpartum in high-risk women and at higher doses. Not consistent across all trials. | Benefit attenuates at four to six weeks. Meta-analytic evidence does not show sustained reduction in PPD incidence at longer follow-up. | Inconsistent across trials. Does not support routine prophylactic use in peripartum setting. Does not affect racemic ketamine's well-established efficacy for TRD in non-peripartum populations. |
| Esketamine (S-ketamine) | BMC Anesthesiology 2022 (PCIA); JAD 2023 dose-finding; Wang et al. BMJ 2024 (landmark, NNT approximately 5); JAMA Network Open 2024 and 2025; Darwish and Shi meta-analyses 2025 | Consistent reduction in PPD incidence and EPDS scores at one week postpartum across multiple trials and meta-analyses. Concurrent analgesic benefit. | Statistically significant reduction in PPD incidence maintained at four to six weeks in multiple trials and meta-analyses. Most durable evidence in this space. | More consistent and durable than racemic ketamine. Strongest evidence is in women with existing antenatal depressive symptoms undergoing cesarean. Not yet an outpatient treatment indication. |
What About Treatment for Established PPD?
Everything we have covered so far is about prevention. That is a very different clinical question from what we want to address now: what about the mother who is already sitting in front of you with established postpartum depression? What does the evidence say about using ketamine or esketamine as an actual treatment for PPD that has already taken hold?
The honest answer is: much less, and we need to be clear about that distinction.
A 2022 narrative review published in Annals of Clinical Psychiatry synthesized four clinical trials and reports where ketamine was administered to postpartum populations in a treatment-oriented context. The conclusion was cautiously optimistic: ketamine may be favorable in this setting given its rapid antidepressant and analgesic effects, short infusion time, and rapid clearance from the maternal bloodstream, but the evidence is insufficient to support routine use for established PPD. The authors explicitly called for more interventional trials focused on treatment rather than prevention.
A 2024 systematic review in a Wiley psychiatry journal examining eight randomized trials of perinatal ketamine around cesarean delivery reached a similar conclusion. Ketamine can reduce PPD symptoms in most studies, but not all trials are positive, and dosing, timing, and causal relationships remain unclear.
The Center for Women's Mental Health at Massachusetts General Hospital, one of the most respected voices in reproductive psychiatry, published a 2024 clinical commentary specifically addressing whether ketamine or esketamine is an option for the treatment of postpartum depression. Their conclusion was measured and worth stating plainly: the data, particularly for esketamine, are promising, but most of it involves anesthetic adjunct use around cesarean for prevention, not treatment of established PPD. More trials are needed before routine clinical adoption is warranted.
The woman who is six weeks postpartum, struggling to get out of bed, unable to bond with her baby, and not responding to first-line antidepressants is arguably the patient most relevant to our community. And she is almost entirely absent from this research.
Ethical and Clinical Considerations
Even where the preventive data for esketamine are stronger, there are real complexities that any clinician thinking about this population needs to sit with.
The first is lactation and infant exposure. Ketamine and esketamine can be excreted into breast milk, and existing clinical guidance on nursing after administration is sparse and not well standardized. The cesarean trials we discussed largely did not address breastfeeding or infant outcomes in depth. Any provider considering ketamine or esketamine in a postpartum patient needs to have an explicit, documented conversation about breastfeeding, timing of administration, and pumping-and-discarding practices, ideally in consultation with the patient's OB and pediatric teams.
The second is neurodevelopmental data, or more accurately the lack of it. We do not have long-term follow-up data on the children of mothers who received ketamine or esketamine peripartum. The trials in this space had follow-up windows of days to six weeks and focused on maternal outcomes. What that exposure means for infant neurodevelopment over months and years is an open question. That does not mean the answer is negative, but it does mean we do not know, and patients deserve to know that we do not know.
The third is informed consent in the peripartum period. Obtaining truly informed consent from a woman who is in active labor, recovering from surgery, or in the immediate postpartum window is genuinely complex. The emotional and physiological state of that period affects capacity, comprehension, and voluntariness in ways that require careful clinical attention.
The fourth is the tension between the appeal of rapid relief in severe or suicidal postpartum depression and the need to avoid premature widespread use before the evidence base matures. Postpartum depression with suicidal ideation is a psychiatric emergency. The idea that a single infusion could meaningfully reduce that risk within hours is genuinely compelling, and for individual clinicians facing individual patients in crisis, the temptation to act on that promise is understandable. But the treatment-focused data are thin, the populations studied are specific, and the clinical infrastructure to support safe peripartum ketamine use outside of a hospital anesthesia context is not yet well defined.
Compassion and caution are not opposites here. They have to coexist.
Five Research Gaps Worth Knowing
Naming the gaps honestly is just as important as summarizing what we know. Here is where the field currently falls short.
The first and most significant gap is the absence of well-powered, treatment-focused trials. Almost everything we discussed is about prevention in a perioperative context. The woman with established postpartum depression who is not responding to first-line treatment is almost entirely absent from this research literature.
The second gap is standardization. Across the trials we covered, dosing ranged from approximately 0.2 mg/kg to 0.5 mg/kg and beyond. Routes of administration included IV bolus, IV infusion, subcutaneous injection, and PCIA. Timing ranged from intraoperative to immediately post-delivery to 48 hours postoperatively. We cannot draw clean, practice-ready conclusions from a literature that has not yet agreed on what exactly it is testing.
The third gap is population diversity. The majority of these trials were conducted in China, in tertiary hospital settings, with relatively homogeneous patient populations. How these findings translate to the diverse and complex patient populations seen in U.S. clinical practice across different ethnicities, socioeconomic contexts, comorbidities, and healthcare systems is genuinely unknown.
The fourth gap is long-term follow-up for both maternal outcomes and child neurodevelopment. Most trials measured outcomes at 28 to 42 days postpartum. Almost none looked beyond that window. For an intervention given at one of the most biologically and neurologically sensitive periods of a woman's life, that is a meaningful limitation.
The fifth gap is breastfeeding. Across this entire literature, breastfeeding outcomes and infant exposure data are remarkably thin. Perinatal guidelines explicitly note insufficient safety data for ketamine in pregnancy and lactation and recommend caution. That has to change before any of this moves toward routine clinical practice.
| Five research gaps in ketamine and esketamine for postpartum depression | ||
| Research gap | Why it matters | What we need |
|---|---|---|
| Treatment-focused trials | Almost all existing peripartum data studies prevention around the time of cesarean delivery, not treatment of established PPD in an outpatient setting. The woman already diagnosed with postpartum depression who is not responding to first-line treatment is largely absent from this research. | Well-powered randomized controlled trials studying ketamine and esketamine as active treatment for established PPD, not as a perioperative prophylactic adjunct. |
| Standardization of dosing and timing | Across current trials, dosing ranges from approximately 0.2 mg/kg to 0.5 mg/kg and beyond. Routes of administration include IV bolus, IV infusion, subcutaneous injection, and PCIA. Timing ranges from intraoperative to 48 hours postoperatively. Heterogeneity across trials makes it impossible to draw clean, practice-ready conclusions. | Agreed-upon dosing protocols, administration routes, and timing windows that allow meaningful cross-trial comparison and support standardized clinical adoption. |
| Population diversity | The overwhelming majority of peripartum ketamine and esketamine trials were conducted in China in tertiary hospital settings with relatively homogeneous patient populations. How these findings translate to diverse U.S. patient populations across different ethnicities, socioeconomic contexts, and healthcare systems is unknown. | Multicenter trials conducted across diverse geographies and patient populations, including community hospital settings and underserved populations, to establish generalizability. |
| Long-term follow-up | Most trials measured outcomes at 28 to 42 days postpartum. Almost none extended beyond six weeks. For an intervention given during one of the most biologically and neurologically sensitive windows of a woman's life, that follow-up window is a meaningful limitation for both maternal outcomes and child neurodevelopment. | Extended follow-up protocols measuring maternal mood, functional outcomes, and infant neurodevelopmental milestones at six months, one year, and beyond. |
| Breastfeeding and infant exposure data | Ketamine and esketamine can be excreted into breast milk. Perinatal trials largely did not monitor breastfeeding practices systematically or report infant outcomes. Current clinical guidelines explicitly note insufficient safety data for ketamine in lactation. This gap must close before any of this moves toward routine clinical practice. | Dedicated lactation pharmacokinetic studies measuring ketamine and esketamine concentration in breast milk, clearance timing, and infant exposure levels, along with infant safety outcome reporting in future RCTs. |
What This Means for Your Practice Right Now
Three things worth taking away from all of this.
First, know the literature. Your patients are going to come to you having read something, having seen a headline, having heard a podcast. Being able to speak honestly and precisely about what the evidence does and does not show is part of serving them well. The prevention versus treatment distinction alone will clarify more conversations than almost any other single piece of clinical framing you can offer.
Second, treat peripartum ketamine as a coordinated care conversation, not a solo clinical decision. The peripartum period intersects obstetrics and reproductive psychiatry in ways that require careful collaboration. If you have a postpartum patient who you believe might benefit from ketamine therapy for established depression, that conversation needs to involve her OB, her psychiatrist if she has one, and a careful and documented informed consent process that addresses lactation, infant exposure, and the investigational nature of the treatment in this specific population.
Third, watch this space. The research is moving. The BMJ and JAMA Network Open trials we discussed are recent and are generating momentum for more treatment-focused work. Organizations like ASKP3 are working to develop standardized practice guidelines for IV ketamine in mood disorders and pain, and it is reasonable to expect that perinatal protocols will evolve as the data mature. The evidence base we have today is not the evidence base we will have in three to five years.
The goal is not to shut the door on this conversation. It is to make sure that when we walk through it, we do so with our eyes open, our protocols solid, and our patients fully informed.
That is what cautious optimism looks like in practice.
Keep Reading: If this post raised questions you want to go deeper on, these are worth your time.
The Clinician's Guide to Ketamine Therapy: Patient Selection and Protocols | Part 3 Patient selection is where the clinical judgment lives. This guide covers the screening and protocol considerations that inform which patients are good candidates for ketamine therapy, including how to think about complex or vulnerable populations.
The Set and Setting Flip: What a Leading Neuroscientist's Hypothesis Could Mean for Your Ketamine Patients If the peripartum research made you think harder about what the brain is doing during a ketamine session, this post covers a newly published hypothesis about how ketamine works at the circuit level and what it might mean for how we think about patient state during treatment.
13 Best Practices for Ketamine Therapy Clinics The clinical foundation that protects your patients and your practice. A practical framework covering everything from screening to integration support that applies across patient populations.
Professional Education Disclaimer: This content is intended exclusively for licensed healthcare professionals and should not be used by patients for self-treatment or self-education. The information presented reflects individual provider experiences and should not replace clinical judgment, professional training, or comprehensive research. Healthcare providers must conduct their own due diligence, consult current literature, and evaluate treatment approaches within their specific practice context and regulatory environment. This educational content does not constitute medical advice for specific patients or clinical situations - treatment decisions should always be based on individual patient assessment and adherence to professional medical standards.
Frequently Asked Questions
What is postpartum depression and how is it different from postpartum psychosis?
Postpartum depression is a major depressive episode associated with childbirth, characterized by persistent low mood, loss of interest, fatigue, difficulty bonding with the infant, and in severe cases suicidal ideation. Epidemiologic data suggest that depressive conditions in the first year postpartum affect roughly 10 to 20 percent of mothers, with major depression occurring in approximately 7 to 13 percent depending on the study and country. In clinical practice, postpartum depression typically refers to depression emerging within the first year after birth, even though DSM-5 uses the peripartum onset specifier for episodes beginning during pregnancy or within four weeks postpartum.
Postpartum psychosis is a distinct and rare psychiatric emergency involving hallucinations, delusions, and disorganized thinking. It is not simply severe PPD and requires urgent specialist care. Because ketamine can exacerbate psychotic symptoms, postpartum psychosis is generally considered a contraindication, or at minimum a situation requiring extreme caution, for ketamine therapy rather than an indication for it.
Does ketamine work for postpartum depression?
The answer depends entirely on how that question is framed. For prevention of postpartum depression in high-risk obstetric populations around the time of cesarean delivery, there is a meaningful body of research, particularly for esketamine, showing a reduced risk of PPD in the weeks that follow. These studies administer sub-anesthetic ketamine or esketamine perioperatively as anesthetic or analgesic adjuncts and measure depression outcomes at one to six weeks postpartum. For treatment of established postpartum depression in an outpatient setting, the evidence is much thinner. A 2022 narrative review identified only four clinical trials or reports of ketamine in postpartum populations in a treatment-oriented context and concluded that while ketamine appears promising, evidence is insufficient to support routine use for established PPD. Subsequent systematic reviews echo this distinction: prevention data are accumulating, but well-powered treatment-focused trials in women already diagnosed with PPD have not yet been conducted. The prevention versus treatment distinction is the most important lens for reading this literature.
What is the difference between racemic ketamine and esketamine for postpartum depression?
Racemic ketamine is a mixture of two molecular enantiomers, the S and R forms. Esketamine isolates the S-enantiomer, which has stronger NMDA receptor binding affinity and is hypothesized to have more potent antidepressant effects at equivalent or lower doses.
In the peripartum evidence base, racemic ketamine shows a short-term preventive signal, with meta-analytic subgroup analysis suggesting reduced PPD incidence at about one week postpartum, but that benefit does not persist at four to six weeks and individual trial results are heterogeneous. Esketamine shows a more consistent and durable effect, with multiple randomized trials and meta-analyses demonstrating significant reductions in PPD incidence and EPDS scores at one and approximately six weeks postpartum, particularly in high-risk women, and with concurrent analgesic benefit.
The 2024 BMJ trial by Wang et al., focused on IV esketamine in women with existing prenatal depressive symptoms, reported major depressive episodes at 42 days in 6.7 percent of the esketamine group versus 25.4 percent in the placebo group, corresponding to a number needed to treat of approximately five to prevent one major depressive episode.
Importantly, this peripartum prevention literature does not reflect negatively on racemic ketamine's well-established efficacy for treatment-resistant depression in non-peripartum populations, which rests on a separate and more robust evidence base.
Is ketamine safe to use in postpartum patients who are breastfeeding?
This is one of the most significant gaps in the current literature. Ketamine and esketamine can be excreted into breast milk, and clinical guidance on nursing after administration is sparse and not well standardized. The peripartum trials in this space largely did not monitor breastfeeding practices systematically or report infant neurodevelopmental outcomes. Most follow-up focused on maternal mood and pain over days to several weeks.
Perinatal clinical guidelines and expert reviews explicitly note insufficient safety data for ketamine in pregnancy and lactation and recommend cautious, individualized decision-making rather than routine use. Any provider considering ketamine in a breastfeeding patient should have an explicit, documented conversation about timing, pumping-and-discarding practices, and the limits of current safety data, ideally in coordination with the patient's obstetric and pediatric teams.
What does the research on esketamine for postpartum depression show?
The most rigorous single trial is the 2024 BMJ study by Wang et al., a double-blind placebo-controlled RCT across five tertiary hospitals in China. In mothers with prenatal depressive symptoms (EPDS of 10 or higher), a single 0.2 mg/kg IV esketamine infusion after childbirth reduced major depressive episodes at 42 days postpartum to 6.7 percent versus 25.4 percent in the placebo group, with lower EPDS and Hamilton scores and transient neuropsychiatric side effects that resolved within 24 hours.
Multiple meta-analyses, including the 2025 Darwish and Shi analyses pooling thousands of women across randomized controlled trials, show consistent reductions in short-term and four to six week PPD risk and EPDS scores with perioperative esketamine, along with reduced postoperative pain scores. These studies report increased transient adverse effects such as dizziness, blurred vision, hallucinations, and diplopia, but serious adverse events are rare at the doses used.
This esketamine data is almost entirely from prevention trials in perioperative hospital settings, mostly cesarean deliveries in China, and not from outpatient treatment of established PPD.
Should ketamine clinics be treating postpartum depression?
Not routinely, based on current evidence. The peripartum ketamine and esketamine data that exists is largely prevention-focused and was conducted in hospital-based anesthesia or labor-analgesia settings with specific high-risk obstetric populations. The evidence base for treating established postpartum depression with ketamine in an outpatient context has not yet matured to the point where routine clinical adoption is warranted.
For providers who believe an individual patient with established PPD might benefit from ketamine therapy, that decision should involve coordination with the patient's obstetric provider and ideally a reproductive psychiatrist. It requires a careful, documented informed consent process addressing lactation, infant exposure, and the investigational nature of ketamine in this specific population, as well as a clear understanding of what the research currently does and does not support.
References
Clinical Background and Burden of Perinatal Depression
BMJ Best Practice. Postpartum Depression. https://bestpractice.bmj.com/topics/en-us/512
StatPearls. Postpartum Depression. https://www.ncbi.nlm.nih.gov/books/NBK519070/
American Psychiatric Association. What is Peripartum Depression? https://www.psychiatry.org/patients-families/peripartum-depression/what-is-peripartum-depression
Racemic Ketamine: Peripartum Trials
Esketamine: Peripartum Trials
Meta-Analyses and Systematic Reviews
Treatment of Established PPD and Ethical Considerations
General Resources and Expert Commentary
Center for Women's Mental Health, Massachusetts General Hospital. Is Ketamine or Esketamine an Option for the Treatment of Postpartum Depression? https://womensmentalhealth.org/posts/ketamine-esketamine-for-postpartum-depression/
A review of the latest RCTs and meta-analyses on ketamine and esketamine for postpartum depression, including key evidence gaps and practice implications.
A review of the latest RCTs and meta-analyses on ketamine and esketamine for postpartum depression, including key evidence gaps and practice implications.